The interaction between glucose levels and body mass index on the regulation of the circulating sphingolipidome in humans
- 1 May 2026
- journal article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 330 (5) , E589-E605
Abstract
Sphingolipid glycosylation is an enzymatic process that does not follow the pattern of nonenzymatic hemoglobin glycosylation. Unexpectedly, hexosyl- and lactosylceramides decreased in impaired fasting glucose and diabetes, with and without obesity. On the other hand, dihydroceramides increased in overweight/obesity with prediabetes/diabetes. The circulating sphingolipidome is differentially regulated in humans according to sex, glucose, and BMI.Keywords
Funding Information
- Regione Lombardia (GR-2011 02350447)
- Ministero dell’Istruzione, dell’Università e della Ricerca (GR-2011 02350447)
- Università degli Studi di Milano (LINEA 2 DEL PIANO DI SOSTEGNO ALLA RICERCA PSR2020_DIP_013_PARONI)
- Ministero dell'Università e della Ricerca (PNC 0000001 D3_4 Health CUP: B53C22006080001)
- Università degli Studi di Milano (LINEA 2 DEL PIANO DI SOSTEGNO ALLA RICERCA PSR2020_DIP_013_PARONI)
- Università degli Studi di Milano (F_DOTAZIONE_2025_DIP_013)
This publication has 85 references indexed in Scilit:
- Ceramides as Emerging Players in Cardiovascular Disease: Focus on Their Pathogenetic Effects and Regulation by DietAdvances in Nutrition, 2024
- The function of sphingolipids in different pathogenesis of Alzheimer's disease: A comprehensive reviewBiomedicine & Pharmacotherapy, 2024
- On the role of sphingolipids in cell survival and death2020
- Sphingolipids as Biomarkers of Disease2019
- Plasma Dihydroceramides Are Diabetes Susceptibility Biomarker Candidates in Mice and HumansCell Reports, 2017
- GM3 and diabetesGlycoconjugate Journal, 2014
- Sphingolipids in Obesity, Type 2 Diabetes, and Metabolic Disease2013
- An Overview of Sphingolipid Metabolism: From Synthesis to Breakdown2010
- Impaired regulation of the TNF-α converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humansDiabetologia, 2009
- Statistische Datenanalyse2002